文献リスト

1) Strotmeier J, Lee K, Völker AK, et al. Botulinum neurotoxin serotype D attacks neurons via two carbohydrate binding sites in a ganglioside dependent manner. Biochem J. 2010; 431: 207-16

2) Peng L, Tepp WH, Johnson EA, et al. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 2011; 7: e1002008

3) Tsukamoto K, Kohda T, Mukamoto M, et al. Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins. J Biol Chem. 2005; 280: 35164-71

4) Dong M, Tepp WH, Liu H, et al. Mechanism of botulinum neurotoxin B and G entry into hippo-campal neurons. J Cell Biol. 2007; 179: 1511-22

5) Rummel A, Hafner K, Mahrhold S, et al. Botulinum neurotoxins C, E and F bind gangli-osides via a conserved binding site prior to stimu-lation dependent uptake with botulinum neuro-toxin f utilising the three isoforms of SV2 as second receptor. J Neurochem. 2009; 110: 1942-54

6) Meng J, Wang J, Lawrence G, et al. Synapto-brevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007; 120: 2864-74

7) Nuemket N, Tanaka Y, Tsukamoto K, et al. Preliminary X-ray crystallographic study of the receptor-binding domain of the D/C mosaic neurotoxin from Clostridium botulinum. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010; 66: 608-10

8) Schmitt J, Karalewitz A, Benefield DA, et al. Structural analysis of botulinum neurotoxin type G receptor binding. Biochemistry. 2010; 49: 5200-5

9) Fernandez-Salas E, Garay P, Jacky B, et al. Identification of the fibroblast growth factor receptor FGFR3 as a component of the receptor complex for botulinum neurotoxin type A. Toxicon. 2008; 51 Suppl 1: 3

10) Oguma K, Inoue K, Fujinaga Y, et al. Structure and function of Clostridium botulinum progenitor toxin. J Toxicol-Toxin Rev. 1999; 18: 17-34

11) Lietzow MA, Gielow ET, Le D, et al. Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denatu-ring capillary electrophoresis. Protein J. 2008; 27: 420-5

12) Eisele K-H, Fink K, Vey M, et al. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011; 57: 555-65

13) Koshy J, Sharabi1 S, Feldman E, et al. Effect of dietary zinc supplementation on botulinum toxin treatments: a modified randomized, double-blind, placebo-controlled, crossover pilot study (abstr). ASOPRS 41st Annual Fall Scientific Symposium (Chicago, IL). 2010. p.8

14) Heckmann M, Teichmann B, Schröder U, et al. Pharmacologic denervation of frown muscles enhances baseline expression of heppiness and decreases baseline expression of anger, sadness, and fear. J Am Acad Dermatol. 2003; 49: 213-6

15) Hennenlotter A, Dresel C, Castrop F, et al. The link between facial feedback and neural activity within central circuitries of emotion--new insights from botulinum toxin-induced denervation of frown muscles. Cereb Cortex. 2009; 19: 537-42

16) Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: A case series. Dermatol Surg. 2006; 32: 645-9; discussion 649-50

17) Lewis MB, Bowler PJ. Botulinum toxin cosmetic therapy correlates with a more positive mood. J Cosmet Dermatol. 2009; 8: 24-6

18) Alam M, Barrett KC, Hodapp RM, et al. Botulinum toxin and the facial feedback hypoth-esis: can looking better make you feel happier？ J Am Acad Dermatol. 2008; 58: 1061-72

19) Havas DA, Glenberg AM, Gutowski KA, et al. Cosmetic use of botulinum toxin-A affects processing of emotional language. Psychol Sci. 2010; 21: 895-900

20) Davis JI, Senghas A, Brandt F, et al. The effects of Botox injections on emotional experience. Emotion. 2010; 10: 433-40

21) Neal DT, Chartrand TL. Embodied emotion perception: amplifying and dampening facial feedback modulates emotion perception accu-racy. Soc Psychol Personal Sci. 2011 [Epub ahead of print]

22) Antonucci F, Rossi C, Gianfranceschi L, et al. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008; 28: 3689-96

23) 鳥居恭司, 赤池紀生, 原川哲博, 他. 低分子量ボツリヌス毒素製剤A2NTXはA1毒素よりも拡散しない(会). 臨床神経. 2009; 49: 1000

24) 清水利彦, 柴田 護, 鳥海春樹, 他. A型ボツリヌス毒素の三叉神経節における TRPV1 発現への影響—投与量による比較検討—(会). 日頭痛会誌. 2009; 36: 84

25) Bach-Rojecky L, Lackovic Z. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav. 2009; 94: 234-8

26) Lee W-H, Shin T-J, Kim HJ, et al. Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced nociceptive re-sponses in mice. Anesth Analg. 2011; 112: 228-35

27) Meng J, Ovsepian SV, Wang J, et al. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci. 2009; 29: 4981-92

28) Wang J, Meng J, Lawrence GW, et al. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, trans-location, and protease domains to their func-tional characteristics. J Biol Chem. 2008; 283: 16993-7002

29) Chen S, Barbieri JT. Engineering botulinum neurotoxin to extend therapeutic intervention. Proc Natl Acad Sci U S A. 2009; 106: 9180-4

30) Chaddock JA, Purkiss JR, Duggan MJ, et al. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neuro-transmitter release in vitro. Growth Factors. 2000; 18: 147-55

31) Chaddock JA, Purkiss JR, Friis LM, et al. Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endo-peptidase derivative of Clostridium botulinum neurotoxin type A. Infect Immun. 2000; 68: 2587-93

32) Duggan MJ, Quinn CP, Chaddock JA, et al. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem. 2002; 277: 34846-52

33) Foster KA, Adams EJ, Durose L, et al. Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics. Neurotox Res. 2006; 9: 101-7

34) Bade S, Rummel A, Reisinger C, et al. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. J Neurochem. 2004; 91: 1461-72

35) Zhang P, Ray R, Singh BR, et al. An efficient drug delivery vehicle for botulism countermeasure. BMC Pharmacology. 2009; 9: 12

36) Band PA, Blais S, Neubert TA, et al. Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery. Protein Expr Purif. 2010; 71: 62-73

37) Fahrer J, Plunien R, Binder U, et al. Genetically engineered clostridial C2 toxin as a novel deliv-ery system for living mammalian cells. Bioconjug Chem. 2010; 21: 130-9

38) Fahrer J, Funk J, Lillich M, et al. Internalization of biotinylated compounds into cancer cells is promoted by a molecular Trojan horse based upon core streptavidin and clostridial C2 toxin. Naunyn Schmiedebergs Arch Pharmacol. 2011; 383: 263-73

39) Knight A, Carvajal J, Schneider H, et al. Non-viral neuronal gene delivery mediated by the HC fragment of tetanus toxin. Eur J Biochem. 1999; 259: 762-9

40) Box M, Parks DA, Knight A, et al. A multi-domain protein system based on the HC fragment of tetanus toxin for targeting DNA to neuronal cells. J Drug Target. 2003; 11: 333-43

41) Andreu A, Fairweather N, Miller AD. Clostridium neurotoxin fragments as potential targeting moieties for liposomal gene delivery to the CNS. Chembiochem. 2008; 9: 219-31

42) Schneider H, Groves M, Muhle C, et al. Re-targeting of adenoviral vectors to neurons using the Hc fragment of tetanus toxin. Gene Ther. 2000; 7: 1584-92

43) Drachman DB, Adams RN, Balasubramanian U, et al. Strategy for treating motor neuron diseases using a fusion protein of botulinum toxin binding domain and streptavidin for viral vector access: work in progress. Toxins. 2010; 2: 2872-89

44) Pickett A, Perrow K. Towards new uses of botulinum toxin as a novel therapeutic tool. Toxins. 2011; 3: 63-81

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp